Lorlatinib Follow-up Data Show Prolonged Progression-Free Survival in ALK-Positive Advanced Lung Cancer
Pfizer today announced long-term follow-up results from the CROWN study7.8Phase III trial evaluating lorlatinib (▼Lorviqua®),…
0 Comments